Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy.

Joseph S, Vingill S, Jahn O, Fledrich R, Werner HB, Katona I, Möbius W, Mitkovski M, Huang Y, Weis J, Sereda MW, Schulz JB, Nave KA, Stegmüller J.

J Neurosci. 2019 May 13. pii: 3094-18. doi: 10.1523/JNEUROSCI.3094-18.2019. [Epub ahead of print]

PMID:
31085610
2.

Publisher Correction: NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies.

Fledrich R, Akkermann D, Schütza V, Abdelaal TA, Hermes D, Schäffner E, Soto-Bernardini MC, Götze T, Klink A, Kusch K, Krueger M, Kungl T, Frydrychowicz C, Möbius W, Brück W, Mueller WC, Bechmann I, Sereda MW, Schwab MH, Nave KA, Stassart RM.

Nat Commun. 2019 Apr 16;10(1):1840. doi: 10.1038/s41467-019-09886-4.

3.

NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies.

Fledrich R, Akkermann D, Schütza V, Abdelaal TA, Hermes D, Schäffner E, Soto-Bernardini MC, Götze T, Klink A, Kusch K, Krueger M, Kungl T, Frydrychowicz C, Möbius W, Brück W, Mueller WC, Bechmann I, Sereda MW, Schwab MH, Nave KA, Stassart RM.

Nat Commun. 2019 Apr 1;10(1):1467. doi: 10.1038/s41467-019-09385-6. Erratum in: Nat Commun. 2019 Apr 16;10(1):1840.

4.

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

Prukop T, Stenzel J, Wernick S, Kungl T, Mroczek M, Adam J, Ewers D, Nabirotchkin S, Nave KA, Hajj R, Cohen D, Sereda MW.

PLoS One. 2019 Jan 16;14(1):e0209752. doi: 10.1371/journal.pone.0209752. eCollection 2019.

5.

Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy.

Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, Lüchtenborg C, Prukop T, Stenzel J, Rahman RU, Hermes D, Ewers D, Möbius W, Ruhwedel T, Katona I, Weis J, Klein D, Martini R, Brück W, Müller WC, Bonn S, Bechmann I, Nave KA, Stassart RM, Sereda MW.

Nat Commun. 2018 Aug 2;9(1):3025. doi: 10.1038/s41467-018-05420-0.

6.

Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.

Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Schnizer TJ, Prukop T, Garcia-Angarita N, Czesnik D, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Walter MC, Triaal C, Hogrel JY, Dubourg O, Schenone A, Baets J, De Jonghe P, Shy ME, Horvath R, Pareyson D, Seeman P, Young P, Sereda MW.

J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):941-952. doi: 10.1136/jnnp-2017-315721. Epub 2017 Aug 31.

PMID:
28860329
7.

Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy.

Kleinecke S, Richert S, de Hoz L, Brügger B, Kungl T, Asadollahi E, Quintes S, Blanz J, McGonigal R, Naseri K, Sereda MW, Sachsenheimer T, Lüchtenborg C, Möbius W, Willison H, Baes M, Nave KA, Kassmann CM.

Elife. 2017 May 4;6. pii: e23332. doi: 10.7554/eLife.23332.

8.

Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.

Sociali G, Visigalli D, Prukop T, Cervellini I, Mannino E, Venturi C, Bruzzone S, Sereda MW, Schenone A.

Neurobiol Dis. 2016 Nov;95:145-57. doi: 10.1016/j.nbd.2016.07.017. Epub 2016 Jul 16.

PMID:
27431093
9.

Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair.

Quintes S, Brinkmann BG, Ebert M, Fröb F, Kungl T, Arlt FA, Tarabykin V, Huylebroeck D, Meijer D, Suter U, Wegner M, Sereda MW, Nave KA.

Nat Neurosci. 2016 Aug;19(8):1050-1059. doi: 10.1038/nn.4321. Epub 2016 Jun 13.

10.

Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking.

Patzig J, Kusch K, Fledrich R, Eichel MA, Lüders KA, Möbius W, Sereda MW, Nave KA, Martini R, Werner HB.

Glia. 2016 Jan;64(1):155-74. doi: 10.1002/glia.22922. Epub 2015 Sep 22.

PMID:
26393339
11.

The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy.

Pehlivan D, Beck CR, Okamoto Y, Harel T, Akdemir ZH, Jhangiani SN, Withers MA, Goksungur MT, Carvalho CM, Czesnik D, Gonzaga-Jauregui C, Wiszniewski W, Muzny DM, Gibbs RA, Rautenstrauss B, Sereda MW, Lupski JR.

Genet Med. 2016 May;18(5):443-51. doi: 10.1038/gim.2015.124. Epub 2015 Sep 17.

12.

Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease.

Epplen DB, Prukop T, Nientiedt T, Albrecht P, Arlt FA, Stassart RM, Kassmann CM, Methner A, Nave KA, Werner HB, Sereda MW.

Ann Clin Transl Neurol. 2015 Aug;2(8):787-96. doi: 10.1002/acn3.219. Epub 2015 Jun 24.

13.

A brief review of recent Charcot-Marie-Tooth research and priorities.

Ekins S, Litterman NK, Arnold RJ, Burgess RW, Freundlich JS, Gray SJ, Higgins JJ, Langley B, Willis DE, Notterpek L, Pleasure D, Sereda MW, Moore A.

F1000Res. 2015 Feb 26;4:53. doi: 10.12688/f1000research.6160.1. eCollection 2015. Review.

14.

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.

Chumakov I, Milet A, Cholet N, Primas G, Boucard A, Pereira Y, Graudens E, Mandel J, Laffaire J, Foucquier J, Glibert F, Bertrand V, Nave KA, Sereda MW, Vial E, Guedj M, Hajj R, Nabirotchkin S, Cohen D.

Orphanet J Rare Dis. 2014 Dec 10;9:201. doi: 10.1186/s13023-014-0201-x.

15.

Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A.

Fledrich R, Stassart RM, Klink A, Rasch LM, Prukop T, Haag L, Czesnik D, Kungl T, Abdelaal TA, Keric N, Stadelmann C, Brück W, Nave KA, Sereda MW.

Nat Med. 2014 Sep;20(9):1055-61. doi: 10.1038/nm.3664. Epub 2014 Aug 24.

PMID:
25150498
16.

Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.

Mannil M, Solari A, Leha A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Walter MC, Rautenstrauss B, Schnizer TJ, Schenone A, Seeman P, Kadian C, Schreiber O, Angarita NG, Fabrizi GM, Gemignani F, Padua L, Santoro L, Quattrone A, Vita G, Calabrese D; CMT-TRIAAL/CMT-TRAUK Group, Young P, Laurà M, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Shy ME, Reilly MM, Pareyson D, Sereda MW.

Neuromuscul Disord. 2014 Nov;24(11):1003-17. doi: 10.1016/j.nmd.2014.06.431. Epub 2014 Jun 19.

PMID:
25085517
17.

Progesterone antagonist therapy in a Pelizaeus-Merzbacher mouse model.

Prukop T, Epplen DB, Nientiedt T, Wichert SP, Fledrich R, Stassart RM, Rossner MJ, Edgar JM, Werner HB, Nave KA, Sereda MW.

Am J Hum Genet. 2014 Apr 3;94(4):533-46. doi: 10.1016/j.ajhg.2014.03.001. Epub 2014 Mar 27.

18.

Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.

Tönges L, Günther R, Suhr M, Jansen J, Balck A, Saal KA, Barski E, Nientied T, Götz AA, Koch JC, Mueller BK, Weishaupt JH, Sereda MW, Hanisch UK, Bähr M, Lingor P.

Glia. 2014 Feb;62(2):217-32. doi: 10.1002/glia.22601. Epub 2013 Dec 6.

PMID:
24311453
19.

A role for Schwann cell-derived neuregulin-1 in remyelination.

Stassart RM, Fledrich R, Velanac V, Brinkmann BG, Schwab MH, Meijer D, Sereda MW, Nave KA.

Nat Neurosci. 2013 Jan;16(1):48-54. doi: 10.1038/nn.3281. Epub 2012 Dec 9.

PMID:
23222914
20.

Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.

Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave KA.

Nature. 2012 Apr 29;485(7399):517-21. doi: 10.1038/nature11007.

21.

Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.

Fledrich R, Stassart RM, Sereda MW.

Br Med Bull. 2012 Jun;102:89-113. doi: 10.1093/bmb/lds010. Epub 2012 May 2. Review.

PMID:
22551516
22.

Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy.

Goebbels S, Oltrogge JH, Wolfer S, Wieser GL, Nientiedt T, Pieper A, Ruhwedel T, Groszer M, Sereda MW, Nave KA.

EMBO Mol Med. 2012 Jun;4(6):486-99. doi: 10.1002/emmm.201200227. Epub 2012 Apr 4.

23.

Lithium enhances remyelination of peripheral nerves.

Makoukji J, Belle M, Meffre D, Stassart R, Grenier J, Shackleford G, Fledrich R, Fonte C, Branchu J, Goulard M, de Waele C, Charbonnier F, Sereda MW, Baulieu EE, Schumacher M, Bernard S, Massaad C.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3973-8. doi: 10.1073/pnas.1121367109. Epub 2012 Feb 21.

24.

A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients.

Fledrich R, Schlotter-Weigel B, Schnizer TJ, Wichert SP, Stassart RM, Meyer zu Hörste G, Klink A, Weiss BG, Haag U, Walter MC, Rautenstrauss B, Paulus W, Rossner MJ, Sereda MW.

Brain. 2012 Jan;135(Pt 1):72-87. doi: 10.1093/brain/awr322. Epub 2011 Dec 20.

PMID:
22189569
25.

Sodium-dependent vitamin C transporter 2 deficiency causes hypomyelination and extracellular matrix defects in the peripheral nervous system.

Gess B, Röhr D, Fledrich R, Sereda MW, Kleffner I, Humberg A, Nowitzki J, Strecker JK, Halfter H, Young P.

J Neurosci. 2011 Nov 23;31(47):17180-92. doi: 10.1523/JNEUROSCI.3457-11.2011.

26.

A role for myelin-associated peroxisomes in maintaining paranodal loops and axonal integrity.

Kassmann CM, Quintes S, Rietdorf J, Möbius W, Sereda MW, Nientiedt T, Saher G, Baes M, Nave KA.

FEBS Lett. 2011 Jul 21;585(14):2205-11. doi: 10.1016/j.febslet.2011.05.032. Epub 2011 May 23.

27.

The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.

Meyer zu Horste G, Miesbach TA, Muller JI, Fledrich R, Stassart RM, Kieseier BC, Coleman MP, Sereda MW.

Neurobiol Dis. 2011 Apr;42(1):1-8. doi: 10.1016/j.nbd.2010.12.006. Epub 2010 Dec 16.

PMID:
21168501
28.

Propagation of spreading depression inversely correlates with cortical myelin content.

Merkler D, Klinker F, Jürgens T, Glaser R, Paulus W, Brinkmann BG, Sereda MW, Stadelmann-Nessler C, Guedes RC, Brück W, Liebetanz D.

Ann Neurol. 2009 Sep;66(3):355-65. doi: 10.1002/ana.21746.

PMID:
19798729
29.

Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models.

Leal A, Huehne K, Bauer F, Sticht H, Berger P, Suter U, Morera B, Del Valle G, Lupski JR, Ekici A, Pasutto F, Endele S, Barrantes R, Berghoff C, Berghoff M, Neundörfer B, Heuss D, Dorn T, Young P, Santolin L, Uhlmann T, Meisterernst M, Sereda MW, Stassart RM, Zu Horste GM, Nave KA, Reis A, Rautenstrauss B.

Neurogenetics. 2009 Oct;10(4):375-376. No abstract available.

30.

Identification of the variant Ala335Val of MED25 as responsible for CMT2B2: molecular data, functional studies of the SH3 recognition motif and correlation between wild-type MED25 and PMP22 RNA levels in CMT1A animal models.

Leal A, Huehne K, Bauer F, Sticht H, Berger P, Suter U, Morera B, Del Valle G, Lupski JR, Ekici A, Pasutto F, Endele S, Barrantes R, Berghoff C, Berghoff M, Neundörfer B, Heuss D, Dorn T, Young P, Santolin L, Uhlmann T, Meisterernst M, Sereda MW, Stassart RM, Meyer zu Horste G, Nave KA, Reis A, Rautenstrauss B.

Neurogenetics. 2009 Oct;10(4):275-87. doi: 10.1007/s10048-009-0183-3. Epub 2009 Mar 17. Erratum in: Neurogenetics. 2009 Oct;10(4):375-6. Sereda, Michael [corrected to Sereda, Michael Werner]; Stassart, Ruth Martha [added].

31.

The SNARE protein SNAP-29 interacts with the GTPase Rab3A: Implications for membrane trafficking in myelinating glia.

Schardt A, Brinkmann BG, Mitkovski M, Sereda MW, Werner HB, Nave KA.

J Neurosci Res. 2009 Nov 15;87(15):3465-79. doi: 10.1002/jnr.22005.

PMID:
19170188
32.

Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system.

Brinkmann BG, Agarwal A, Sereda MW, Garratt AN, Müller T, Wende H, Stassart RM, Nawaz S, Humml C, Velanac V, Radyushkin K, Goebbels S, Fischer TM, Franklin RJ, Lai C, Ehrenreich H, Birchmeier C, Schwab MH, Nave KA.

Neuron. 2008 Aug 28;59(4):581-95. doi: 10.1016/j.neuron.2008.06.028.

33.

Gadofluorine M-enhanced magnetic resonance nerve imaging: comparison between acute inflammatory and chronic degenerative demyelination in rats.

Wessig C, Jestaedt L, Sereda MW, Bendszus M, Stoll G.

Exp Neurol. 2008 Mar;210(1):137-43. Epub 2007 Nov 4.

PMID:
18061168
34.

Mechanisms of disease: inherited demyelinating neuropathies--from basic to clinical research.

Nave KA, Sereda MW, Ehrenreich H.

Nat Clin Pract Neurol. 2007 Aug;3(8):453-64. Review.

PMID:
17671523
35.

Hereditary spastic paraplegia 3A associated with axonal neuropathy.

Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Löfgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zámecník J, Ceulemans B, Erichsen AK, Björck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P.

Arch Neurol. 2007 May;64(5):706-13.

PMID:
17502470
36.

Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.

Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW.

Ann Neurol. 2007 Jan;61(1):61-72. Erratum in: Ann Neurol. 2007 Mar;61(3):282.

PMID:
17262851
37.

Animal models of Charcot-Marie-Tooth disease type 1A.

Sereda MW, Nave KA.

Neuromolecular Med. 2006;8(1-2):205-16. Review.

PMID:
16775377
38.

Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy.

Meyer zu Hörste G, Prukop T, Nave KA, Sereda MW.

J Mol Neurosci. 2006;28(1):77-88. Review.

PMID:
16632877
39.

Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis.

Vigo T, Nobbio L, Hummelen PV, Abbruzzese M, Mancardi G, Verpoorten N, Verhoeven K, Sereda MW, Nave KA, Timmerman V, Schenone A.

Mol Cell Neurosci. 2005 Apr;28(4):703-14.

PMID:
15797717
40.

Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.

Grandis M, Leandri M, Vigo T, Cilli M, Sereda MW, Gherardi G, Benedetti L, Mancardi G, Abbruzzese M, Nave KA, Nobbio L, Schenone A.

Exp Neurol. 2004 Nov;190(1):213-23.

PMID:
15473994
41.

Axonal neuregulin-1 regulates myelin sheath thickness.

Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA.

Science. 2004 Apr 30;304(5671):700-3. Epub 2004 Mar 25.

42.

Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).

Sereda MW, Meyer zu Hörste G, Suter U, Uzma N, Nave KA.

Nat Med. 2003 Dec;9(12):1533-7. Epub 2003 Nov 9.

PMID:
14608378
43.

The AN2 protein is a novel marker for the Schwann cell lineage expressed by immature and nonmyelinating Schwann cells.

Schneider S, Bosse F, D'Urso D, Muller H, Sereda MW, Nave K, Niehaus A, Kempf T, Schnolzer M, Trotter J.

J Neurosci. 2001 Feb 1;21(3):920-33.

44.

Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22.

Niemann S, Sereda MW, Suter U, Griffiths IR, Nave KA.

J Neurosci. 2000 Jun 1;20(11):4120-8.

45.

Altered protein synthesis in sciatic nerve by transgenic overexpression of PMP22 in the CMT rat.

Sereda MW.

Ann N Y Acad Sci. 1999 Sep 14;883:530-2. No abstract available.

PMID:
10586292
46.

The "CMT rat": peripheral neuropathy and dysmyelination caused by transgenic overexpression of PMP22.

Niemann S, Sereda MW, Rossner M, Stewart H, Suter U, Meinck HM, Griffiths IR, Nave KA.

Ann N Y Acad Sci. 1999 Sep 14;883:254-61. Review.

PMID:
10586250
47.

Altered Protein Synthesis in Sciatic Nerve by Transgenic Overexpression of PMP22 in the CMT Rat.

Sereda MW.

Ann N Y Acad Sci. 1999 Oct;883(1):530-532. doi: 10.1111/j.1749-6632.1999.tb08629.x. No abstract available.

PMID:
29086980
48.

The "CMT Rat": Peripheral Neuropathy and Dysmyelination Caused by Transgenic Overexpression of PMP22.

Niemann S, Sereda MW, Rossner M, Stewart H, Suter U, Meinck HM, Griffiths IR, Nave KA.

Ann N Y Acad Sci. 1999 Oct;883(1):254-261. doi: 10.1111/j.1749-6632.1999.tb08587.x.

PMID:
29086932

Supplemental Content

Loading ...
Support Center